Delayed Prostate-specific Antigen Recurrence After Radical Prostatectomy: How to Identify and What Are Their Clinical Outcomes?

Urology

Volumn 74, Issue 3, 2009, Pages 643-647

  Caire, Arthur A ^a   Sun, Leon ^a   Ode, Oludotun ^a   Stackhouse, Danielle A ^a   Maloney, Kelly ^a   Donatucci, Craig ^a   Mouraviev, Vladimir ^a   Polascik, Thomas J ^a   Robertson, Cary N ^a   Albala, David M ^a   Moul, Judd W ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BODY MASS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DELAYED DIAGNOSIS; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATECTOMY;

AGED; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 69249208647     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.02.049     Document Type: Article

References (18)

1. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591-1597
2. Stephenson A.J., Scardino P.T., Eastham J.A., et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 98 (2006) 715-717
3. Jayachandran J., Banez L.L., Levy D.E., et al. Risk stratification for biochemical recurrence in men with positive surgical margins or extracapsular disease after radical prostatectomy: results from the SEARCH database. J Urol 179 (2008) 1791-1796 discussion: 1796
4. Moul J.W., Wu H., Sun L., et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 171 (2004) 1141-1147
5. Trock B.J., Han M., Freedland S.J., et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 299 (2008) 2760-2769
6. Moul J.W., Banez L.L., and Freedland S.J. Rising PSA in nonmetastatic prostate cancer. Oncology (Williston Park) 21 (2007) 1436-1445 1452; discussion: 1449, 1454
7. Blanco Diez A., Armas Molina J., Liminana Canal J.M., et al. Early biochemical failure after radical prostatectomy for prostate cancer. Impact factors?. Actas Urol Esp 32 (2008) 406-410
8. Liss M., Osann K., and Ornstein D. Positive surgical margins during robotic radical prostatectomy: a contemporary analysis of risk factors. BJU Int 102 (2008) 603-608
9. Freedland S.J., Hotaling J.M., Fitzsimons N.J., et al. PSA in the new millennium: a powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes-results from the SEARCH database. Eur Urol 53 (2008) 758-764 discussion: 765-766
10. Douglas T.H., Morgan T.O., McLeod D.G., et al. Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients. Cancer 80 (1997) 107-114
11. Kane C.J., Presti Jr. J.C., Amling C.L., et al. Changing nature of high risk patients undergoing radical prostatectomy. J Urol 177 (2007) 113-117
12. Freedland S.J., Humphreys E.B., Mangold L.A., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294 (2005) 433-439
13. Ward J.F., Blute M.L., Slezak J., et al. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 170 (2003) 1872-1876
14. Mitchell R.E., Shah J.B., Desai M., et al. Changes in prognostic significance and predictive accuracy of Gleason grading system throughout PSA era: impact of grade migration in prostate cancer. Urology 70 (2007) 706-710
15. Shikanov S.A., Thong A., Gofrit O.N., et al. Robotic laparoscopic radical prostatectomy for biopsy Gleason 8-10: prediction of favorable pathologic outcome with preoperative parameters. J Endourol 22 (2008) 1477-1481
16. Buyyounouski M.K., Hanlon A.L., Horwitz E.M., et al. Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy. Int J Radiat Oncol Biol Phys 70 (2008) 59-66
17. Shahani S., Braga-Basaria M., and Basaria S. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrinol Metab 93 (2008) 2042-2049
18. Basaria S. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth. J Androl 29 (2008) 534-539